Results: Between November 11th, 2011, and September 2nd, 2015, 560 patients were matching placebo on day 1-14 of a 21-day cycle, non-progressive patients then received China,15Cancer Center, The First Hospital of Jilin University, Changchun, China, of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Oncology, Jinan Central Hospital, Jinan, China,19The Cancer center, Union Hospital Y. Sun18,G. Wu19, Y. Sun1

Background: Humanized recombinant endostatin (rh-endostatin, Sulijia trial, we enrolled treatment-naı¨ve patients with stage IV NSCLC. Patients were ran-

Methods: advanced non-small cell lung cancer (NSCLC).

Respiratory Medicin, Peking Union Medical College Hospital, Beijing, China,3Department of Medical Oncology, Beigjing Chest Hospital, Capital Medical University, Beijing, China,2Department of Molecular Targeted Drugs, National Cancer Center/Cancer Hospital, Chinese Academy of Xiamen University, Xiamen, China,12Department of Thoracic Oncology, Cancer Center, Shanghai, China,11Department of Respiratory Diseases, First Affiliated Hospital of Nantong, China,9Department of Oncology, Affiliated Hospital, Jiangnan University, Suzhou, China,8Department of Respiratory Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China,7Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China,6Department of Oncology Center, The first People’s Hospital of Changzhou, Changzhou, China,5Department of Oncology, The First Affiliated Hospital of NanJing University, NanJing, China,4Department of Oncology, Cancer Hospital of JiangSu, NanJing, China,3Department of Hematology-Oncology, Samsung Medical Center, Seoul, Republic of Korea, 2Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, 1Division of Hematology-Oncology, National Taiwan University Hospital, Taipei, Taiwan, 4Medical Oncology, Moores UCSD Cancer Center, La Jolla, CA, USA, 5Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain, 6Clinical Research, Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea

Conclusions: Rh-endostatin plus NP improves PFS and is well tolerated as first-line treatment for patients with stage IV NSCLC, especially those with squamous NSCLC and smokers. Rh-endostatin plus NP group and 4

NP group (Hazard Ratio [HR] 0.741, p = 0.0021) and smokers (5 months, HR 0.0124) had significantly longer PFS in the rh-

K. Park1, P.A. Jänne2, C.-J. Yu3, L. Bazhenova4, L. Paz-Ares5, E. Baek6, O. Han6, K.Y. Hong6, H. Kwon6, Y. Kim6, S.R. Kim6

1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea, 2Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, 3Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 4Medical Oncology, Moores UCSD Cancer Center, La Jolla, CA, USA, 5Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain, 6Clinical Research, Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea

Disclosure: All authors have declared no conflicts of interest.

Legal entity responsible for the study: No.

Clinical trial indentification: NCT02485652.